<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383019</url>
  </required_header>
  <id_info>
    <org_study_id>A6641050</org_study_id>
    <nct_id>NCT00383019</nct_id>
  </id_info>
  <brief_title>A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).</brief_title>
  <official_title>A 8-WEEK, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF XALACOM AND XALATAN IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG) OR OCULAR HYPERTENSION (OH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer's Upjohn has merged with Mylan to form Viatris Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in&#xD;
      Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in&#xD;
      efficacy and similarity of safety between Xalacom and Xalatan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2006</start_date>
  <completion_date type="Actual">October 1, 2007</completion_date>
  <primary_completion_date type="Actual">October 1, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Intraocular Pressure (IOP) From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Value at Week 8 minus value at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of IOP From Baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Value at Week 4 minus value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change of IOP From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Xalatan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalacom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>latanoprost 0.005%, one rop once daily in evening</description>
    <arm_group_label>Xalatan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalacom</intervention_name>
    <description>latanoprost 0.005% adn timolol 0.5%, one drop, once daily</description>
    <arm_group_label>Xalacom</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4&#xD;
             weeks or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of no-response to timolol&#xD;
&#xD;
          -  History of trabeculectomy&#xD;
&#xD;
          -  History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nomura Eye Clinic</name>
      <address>
        <city>Ichinomiya</city>
        <state>Aichi</state>
        <zip>491-0837</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsusura Eye Clinic</name>
      <address>
        <city>Ichinomiya</city>
        <state>Aichi</state>
        <zip>491-0858</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasuma Eye Clinic</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TANABE Eye Clinic</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-0054</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzuki Eye Clinic</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsuhashi Eye Clinic</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <zip>275-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohtsuka Eye Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>001-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasamoto Eye Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>001-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohyachi Kyouritsu Eye Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>004-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaimeido Eye Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0020</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Koube</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa university hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lumine Hatano Eye Clinic</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanino clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>248-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aoki eye clinic</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kikuna Yuda Eye Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>222-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujita Eye Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Kokkaido</state>
        <zip>003-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chihara Eye Clinic</name>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyata Eye Hospital</name>
      <address>
        <city>Miyakonojo</city>
        <state>Miyazaki</state>
        <zip>885-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Eye Clinic</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <zip>360-0843</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiraoka Eye Clinic</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1116</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanasaki Eye Clinic</name>
      <address>
        <city>Fuji</city>
        <state>Shizuoka</state>
        <zip>416-0952</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakajima Eye Clinic</name>
      <address>
        <city>Fuji</city>
        <state>Shizuoka</state>
        <zip>419-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshimura Eye &amp; Internal Medical Clinic</name>
      <address>
        <city>Mishima</city>
        <state>Shizuoka</state>
        <zip>411-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muramatsu Ganka Clinic</name>
      <address>
        <city>Susono</city>
        <state>Shizuoka</state>
        <zip>410-1102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochanomizu Inoue Eye Clinic</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Police Hospital</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>102-8161</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio Hachioji Matsumoto Eye Clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manabe Clinic</name>
      <address>
        <city>Hamura</city>
        <state>Tokyo</state>
        <zip>205-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Sugita Eye Center</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <zip>125-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiyosenomori Hospital</name>
      <address>
        <city>Kiyose</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Eye Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohashi Eye Clinic</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takase Ganka Tairamachi Clinic</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>152-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kunitoshi Eye Clinic</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimizu Eye Clinic</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WAKABA Eye Clinic</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>144-052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seijo Clinic</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <zip>157-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yotsuya Shirato Ganka</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>160-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tachihi Bill clinic</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ueno Eye Clinic</name>
      <address>
        <city>Taito-ku</city>
        <state>Tokyo</state>
        <zip>110-015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Eye Hospital</name>
      <address>
        <city>Fujuoka</city>
        <zip>812-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Tennjin Eye Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohshima Hospital of Opthalmology</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kato Eye Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0133</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishi Eye Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>537-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adachi Eye Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>557-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Welfare Pension Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanba Opthalmology</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugita Eye Hospital</name>
      <address>
        <city>Sugita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6641050&amp;StudyName=A%20Study%20Comparing%20Xalacom%20And%20Xalatan%20In%20Patients%20With%20Primary%20Open%20Angle%20Glaucoma%20%28POAG%29%20Or%20Ocular%20Hypertension%20%28OH%29.%0A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <results_first_submitted>October 1, 2008</results_first_submitted>
  <results_first_submitted_qc>April 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2009</results_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>55 centers in Japan</recruitment_details>
      <pre_assignment_details>300 subjects were treated with Xalatan in Run-in period. (Run-in period: subjects treated with Xalatan&amp;#13;(0.005% latanoprost eye drop), one drop, once daily in the evening (20:00-23:00).) Of these, 289 subjects were assigned to groups (144 in KP2035 group and 145 in Xalatan group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="P2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="B2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="289"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Intraocular Pressure (IOP) From Baseline to Week 8</title>
        <description>Value at Week 8 minus value at baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The primary efficacy analysis population was the Intent-to-treat population (ITT) which consisted of all subjects treated with the study drug as randomized. If there were any missing IOP values at Week 8, the data were supplemented by LOCF (Last Observation Carried Forward) using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Intraocular Pressure (IOP) From Baseline to Week 8</title>
          <description>Value at Week 8 minus value at baseline</description>
          <population>The primary efficacy analysis population was the Intent-to-treat population (ITT) which consisted of all subjects treated with the study drug as randomized. If there were any missing IOP values at Week 8, the data were supplemented by LOCF (Last Observation Carried Forward) using data at Week 4.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" lower_limit="-2.92" upper_limit="-2.25"/>
                    <measurement group_id="O2" value="-1.62" lower_limit="-1.96" upper_limit="-1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of IOP From Baseline to Week 4</title>
        <description>Value at Week 4 minus value at baseline</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Change of IOP From Baseline to Week 4</title>
          <description>Value at Week 4 minus value at baseline</description>
          <population>ITT</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" lower_limit="-2.83" upper_limit="-2.17"/>
                    <measurement group_id="O2" value="-1.17" lower_limit="-1.50" upper_limit="-0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=15 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=16 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change of IOP From Baseline to Week 8</title>
        <description>Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of IOP From Baseline to Week 8</title>
          <description>Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.67" lower_limit="-14.40" upper_limit="-10.93"/>
                    <measurement group_id="O2" value="-7.69" lower_limit="-9.42" upper_limit="-5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=18 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</title>
        <description>Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP Reduction of &gt;=2 mmHg From Baseline to Week 8</title>
          <description>Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</title>
        <description>Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP Reduction of &gt;=3 mmHg From Baseline to Week 8</title>
          <description>Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</title>
        <description>Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8</description>
        <time_frame>Week 8</time_frame>
        <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>KP2035 Group</title>
            <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
          </group>
          <group group_id="O2">
            <title>Xalatan Group</title>
            <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an IOP of &lt;=17 mmHg at Week 8</title>
          <description>Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8</description>
          <population>The efficacy analysis population was ITT. If there were any missing IOP values at Week 8, the data were supplemented by LOCF using data at Week 4.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>KP2035 Group</title>
          <description>Subjects were treated with KP2035 (0.005% latanoprost + 0.5% timolol combination eye drop) one drop, once daily in the evening (20:00-23:00).</description>
        </group>
        <group group_id="E2">
          <title>Xalatan Group</title>
          <description>Subjects were treated with Xalatan (0.005% latanoprost), one drop, once daily in the evening (20:00-23:00).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA v10.0">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v10.0">Pyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Meibomianitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Scleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Growth of eyelashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

